vs
Side-by-side financial comparison of Nurix Therapeutics, Inc. (NRIX) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.
Nurix Therapeutics, Inc. is the larger business by last-quarter revenue ($13.6M vs $11.0M, roughly 1.2× Arcus Biosciences, Inc.). Nurix Therapeutics, Inc. runs the higher net margin — -576.1% vs -963.6%, a 387.5% gap on every dollar of revenue. On growth, Nurix Therapeutics, Inc. posted the faster year-over-year revenue change (2.2% vs -52.2%). Nurix Therapeutics, Inc. produced more free cash flow last quarter ($-73.0M vs $-121.0M). Over the past eight quarters, Arcus Biosciences, Inc.'s revenue compounded faster (4.9% CAGR vs -9.5%).
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
NRIX vs RCUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.6M | $11.0M |
| Net Profit | $-78.2M | $-106.0M |
| Gross Margin | — | — |
| Operating Margin | -612.0% | -1036.4% |
| Net Margin | -576.1% | -963.6% |
| Revenue YoY | 2.2% | -52.2% |
| Net Profit YoY | -33.6% | -12.8% |
| EPS (diluted) | $-0.83 | $-0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.6M | $11.0M | ||
| Q3 25 | $7.9M | $6.0M | ||
| Q2 25 | $44.1M | $8.0M | ||
| Q1 25 | $18.5M | $8.0M | ||
| Q4 24 | $13.3M | $23.0M | ||
| Q3 24 | $12.6M | $7.0M | ||
| Q2 24 | $12.1M | $11.0M | ||
| Q1 24 | $16.6M | $10.0M |
| Q4 25 | $-78.2M | $-106.0M | ||
| Q3 25 | $-86.4M | $-135.0M | ||
| Q2 25 | $-43.5M | $0 | ||
| Q1 25 | $-56.4M | $-112.0M | ||
| Q4 24 | $-58.5M | $-94.0M | ||
| Q3 24 | $-49.0M | $-92.0M | ||
| Q2 24 | $-44.5M | $-93.0M | ||
| Q1 24 | $-41.5M | $-4.0M |
| Q4 25 | -612.0% | -1036.4% | ||
| Q3 25 | -1157.7% | -2366.7% | ||
| Q2 25 | -109.7% | -100.0% | ||
| Q1 25 | -340.7% | -1525.0% | ||
| Q4 24 | -486.7% | -447.8% | ||
| Q3 24 | -433.8% | -1500.0% | ||
| Q2 24 | -401.4% | -963.6% | ||
| Q1 24 | -272.6% | -160.0% |
| Q4 25 | -576.1% | -963.6% | ||
| Q3 25 | -1094.8% | -2250.0% | ||
| Q2 25 | -98.7% | — | ||
| Q1 25 | -305.4% | -1400.0% | ||
| Q4 24 | -440.7% | -408.7% | ||
| Q3 24 | -388.9% | -1314.3% | ||
| Q2 24 | -368.4% | -845.5% | ||
| Q1 24 | -250.3% | -40.0% |
| Q4 25 | $-0.83 | $-0.88 | ||
| Q3 25 | $-1.03 | $-1.27 | ||
| Q2 25 | $-0.52 | $0.00 | ||
| Q1 25 | $-0.67 | $-1.14 | ||
| Q4 24 | $-0.74 | $-1.07 | ||
| Q3 24 | $-0.67 | $-1.00 | ||
| Q2 24 | $-0.71 | $-1.02 | ||
| Q1 24 | $-0.76 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $247.0M | $222.0M |
| Total DebtLower is stronger | — | $99.0M |
| Stockholders' EquityBook value | $538.7M | $631.0M |
| Total Assets | $688.1M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $247.0M | $222.0M | ||
| Q3 25 | $78.4M | $238.0M | ||
| Q2 25 | $84.3M | $248.0M | ||
| Q1 25 | $75.9M | $192.0M | ||
| Q4 24 | $110.0M | $150.0M | ||
| Q3 24 | $99.0M | $201.0M | ||
| Q2 24 | $116.8M | $156.0M | ||
| Q1 24 | $49.8M | $185.0M |
| Q4 25 | — | $99.0M | ||
| Q3 25 | — | $98.0M | ||
| Q2 25 | — | $97.0M | ||
| Q1 25 | — | $48.0M | ||
| Q4 24 | — | $48.0M | ||
| Q3 24 | — | $47.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $538.7M | $631.0M | ||
| Q3 25 | $372.3M | $436.0M | ||
| Q2 25 | $447.6M | $549.0M | ||
| Q1 25 | $480.9M | $531.0M | ||
| Q4 24 | $527.0M | $485.0M | ||
| Q3 24 | $376.9M | $565.0M | ||
| Q2 24 | $370.7M | $635.0M | ||
| Q1 24 | $168.7M | $707.0M |
| Q4 25 | $688.1M | $1.1B | ||
| Q3 25 | $522.5M | $974.0M | ||
| Q2 25 | $591.6M | $1.1B | ||
| Q1 25 | $615.0M | $1.2B | ||
| Q4 24 | $669.3M | $1.1B | ||
| Q3 24 | $513.6M | $1.3B | ||
| Q2 24 | $511.0M | $1.2B | ||
| Q1 24 | $312.7M | $1.3B |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.8M | $-120.0M |
| Free Cash FlowOCF − Capex | $-73.0M | $-121.0M |
| FCF MarginFCF / Revenue | -537.4% | -1100.0% |
| Capex IntensityCapex / Revenue | 37.8% | 9.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-263.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.8M | $-120.0M | ||
| Q3 25 | $-57.4M | $-97.0M | ||
| Q2 25 | $-63.2M | $-133.0M | ||
| Q1 25 | $-61.1M | $-132.0M | ||
| Q4 24 | $-48.8M | $-100.0M | ||
| Q3 24 | $-42.2M | $26.0M | ||
| Q2 24 | $-39.7M | $-94.0M | ||
| Q1 24 | $-42.0M | $-2.0M |
| Q4 25 | $-73.0M | $-121.0M | ||
| Q3 25 | $-60.1M | — | ||
| Q2 25 | $-65.8M | — | ||
| Q1 25 | $-64.6M | $-133.0M | ||
| Q4 24 | $-50.9M | $-101.0M | ||
| Q3 24 | $-44.5M | $25.0M | ||
| Q2 24 | $-41.6M | — | ||
| Q1 24 | $-44.8M | $-6.0M |
| Q4 25 | -537.4% | -1100.0% | ||
| Q3 25 | -761.3% | — | ||
| Q2 25 | -149.4% | — | ||
| Q1 25 | -349.9% | -1662.5% | ||
| Q4 24 | -382.8% | -439.1% | ||
| Q3 24 | -353.7% | 357.1% | ||
| Q2 24 | -344.4% | — | ||
| Q1 24 | -270.3% | -60.0% |
| Q4 25 | 37.8% | 9.1% | ||
| Q3 25 | 34.3% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 18.9% | 12.5% | ||
| Q4 24 | 15.8% | 4.3% | ||
| Q3 24 | 18.6% | 14.3% | ||
| Q2 24 | 16.0% | 0.0% | ||
| Q1 24 | 17.4% | 40.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RCUS
| Other | $5.0M | 45% |
| Other Collaboration Revenue | $4.0M | 36% |
| Access Rights And Option Continuation Periods | $2.0M | 18% |
